JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
I issue a hold rating on the iShares US Pharmaceuticals ETF due to fair valuation and mounting near-term headwinds. IHE's portfolio is highly concentrated, with 43% in JNJ and LLY and top 10 holdings
Pharmaceuticals are rebounding as U.S. drug pricing clarity emerges, shifting focus to patent expirations and innovation-driven differentiation. Companies like JNJ and AZN, with diversified portfolios
IMAAVY is an immunoselective FcRn blocker designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies while also preserving B-cell function Warm autoimmune hemolytic anemia is a rar
Vanguard has cemented itself as one of the biggest names in exchange-traded funds (ETFs). The investment advisory firm and global asset manager briefly surpassed BlackRock NYSE: BLK as the largest U.S
Johnson & Johnson (JNJ) maintains a 'Buy' rating, driven by robust Q2 2026 sales growth and pipeline advancements. JNJ's top-performing drugs, DARZALEX and TREMFYA, fueled a 6.6% revenue increase to $
Second-quarter earnings season has largely exceeded expectations.
Johnson & Johnson (JNJ) Discusses FDA Authorization and Market Introduction of OTTAVA Robotic Surgical System Transcript
Wall Street navigated a turbulent week as investors digested the Federal Reserve's latest interest rate decision, a barrage of Big Tech earnings , and renewed geopolitical tensions.
NOBL is outperforming SPY YTD in 2026, returning 12.9% versus SPY's 7.88%, with 45 Aristocrats ahead of SPY. Dividend growth among Aristocrats in 2026 averages 4.10%, with recent increases from ALB, F
CNBC's Jim Cramer said investors are rotating out of some of the market's biggest AI infrastructure winners and into companies with growth drivers outside the data center buildout. He highlighted Cost
Genmab has underperformed so far this year despite strong commercial performance and largely positive pipeline news flow. Strong Q2 royalty product sales (Darzalex +18% Y/Y, Tecvayli +57% Y/Y) support
Forty three Eighteen Advisors LLC bought a new position in Johnson and Johnson (NYSE: JNJ) in the first quarter, according to the company in its most recent disclosure with the SEC. The fund bought 12
Hamilton Point Investment Advisors LLC increased its stake in Johnson and Johnson (NYSE: JNJ) by 6.7% in the first quarter, according to the company in its most recent disclosure with the SEC. The ins
Financiere des Professionnels Fonds d investissement inc. cut its holdings in shares of Johnson and Johnson (NYSE: JNJ) by 19.3% in the first quarter, according to the company in its most recent filin
Wall Street endured another volatile week as investors balanced the start of second-quarter earnings season against persistent weakness in semiconductor stocks and ongoing geopolitical uncertainty.
Johnson & Johnson NYSE: JNJ is an elite income investment because of its Dividend King status, healthy balance sheet, and incredibly strong, defensive business model. Critical details include its prod
The launch of artificial intelligence-powered imaging and mapping capabilities for electrophysiology, early momentum for a drug releasing system for bladder cancer treatment, and progress toward a tab
FTSE 100 down 23 points to 10,506 Miners fall on weaker China GDP Barratt Redrow, ICG, B&M, NextEnergy Solar publish updates 12.13pm: European stocks in...
FTSE 100 down 10 points to 10,479 AstraZeneca tumbles after clinical trial failure Computacenter and Playtech soar after trading updates 4.11pm: FTSE...
Johnson & Johnson has delivered a 43% total return over 9 months, but I maintain a 'Hold' rating due to overvaluation concerns. JNJ's Q1 '26 showed 10% sales growth, but adjusted operational growth wa